Bioinformatics Jobs in USA with Visa Sponsorship
Bioinformatics is a strong field for visa sponsorship because of the specialized computational and biological expertise required. H-1B visa is the primary route, and sponsors include pharma companies, biotech firms, research hospitals, and universities. Academic and research positions may also qualify for J-1 visa or O-1A visas. Having a master's or Ph.D. significantly improves your prospects, and the STEM OPT extension gives you extra runway if you're coming from a student visa. For detailed occupation requirements, see the O*NET profile.
See All Bioinformatics JobsOverview
Showing 5 of 131+ Bioinformatics jobs
Have you applied for this role?
Have you applied for this role?
Have you applied for this role?
Have you applied for this role?
Have you applied for this role?
See all 131+ Bioinformatics jobs
Sign up for free to unlock all listings, filter by visa type, and get alerts for new Bioinformatics roles.
Get Access To All JobsAbout Acrivon Therapeutics, Inc.
Acrivon (NASDAQ: ACRV) is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.
Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2b trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.
In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company’s clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed at DL3. In addition, the company is advancing a preclinical program directed against an undisclosed cell cycle regulatory target.
Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.
Position Overview:
The Senior Scientist/Principal Scientist, Bioinformatics, within the Data Science team will play a central role in developing and applying advanced computational approaches to support drug discovery and development, leveraging Acrivon’s generative phosphoproteomics AP3 platform.
We are seeking a highly accomplished scientist with expertise in building scalable analytical workflows, applying rigorous quantitative methods, and extracting actionable biological insights from large-scale omics data. The successful candidate will lead analyses across proteomics, phosphoproteomics, transcriptomics, and other high-dimensional datasets, integrating these data with systems biology and AI/ML approaches to inform target discovery, mechanism-of-action studies, indication selection, and biomarker identification. Experience in proteomics-driven pathway analysis and network biology will be highly valued.
This individual will work closely within a multidisciplinary environment that includes proteomics, biology, and biomarker teams to maximize the scientific and translational value of Acrivon’s AP3 platform.
This role is based in Watertown, MA.
Duties and Responsibilities:
- Lead computational analysis and interpretation of large-scale proteomics and other multi-omics datasets to support mechanism-of-action studies, indication prioritization, target identification and validation, and biomarker discovery.
- Design, develop, and optimize robust, scalable, and secure computational pipelines for proteomics and multi-omics data analysis.
- Develop and maintain interactive web-based applications and data visualization tools that enable robust analytics within a cloud-based environment.
- Evaluate and incorporate emerging bioinformatics, mass spectrometry proteomics, and AI/ML technologies into data science workflows and analytical pipelines.
- Apply advanced AI/ML approaches, including generative and agentic AI, to enhance biological interpretation, hypothesis generation, and data-driven decision-making.
- Partner closely with proteomics, biology, biomarker, and other cross-functional teams to deliver tailored analyses and actionable biological insights.
Qualifications include:
- D. or M.S. in Bioinformatics, Computational Biology, Computer Science, Engineering, or a related quantitative discipline, with 5+ years of industry experience in a biotechnology or pharmaceutical setting.
- Expertise in the computational analysis, integration, and visualization of large-scale omics datasets, with a particular emphasis on mass spectrometry-based proteomics.
- Proven track record of designing and implementing scalable computational workflows for large-scale omics datasets and translating analytical findings into actionable biological insights.
- Strong programming skills in R and Python, encompassing scripting, data wrangling, statistical analysis, and visualization.
- Experience building interactive analytical tools, visualizations, and enterprise-level web applications using frameworks such as R Shiny, Streamlit, Flask, or Django.
- Experience with cloud computing environments and scalable data infrastructure, including workflow orchestration and data management on cloud platforms.
- Experience with data integration strategies and biological database design, including systems for managing, storing, and retrieving large-scale omics datasets.
- Strong scientific knowledge of oncology, including cancer biology, signaling pathways, biomarkers, and therapeutic modalities.
- Experience with single-cell and/or spatial omics data analysis is preferred.
- Experience applying AI/ML approaches, such as generative AI, agentic workflows, knowledge graphs, large language models, or foundation models, to biological data interpretation or hypothesis generation is preferred.
Acrivon Therapeutics is proud to be an equal opportunity employer and to provide equal opportunities to all employees and applicants for employment without regard to race, color, religion, sex or gender identity, national origin, age, disability, sexual orientation or genetics. In addition to federal law requirements, Acrivon Therapeutics complies with applicable state and local laws governing nondiscrimination in employment.
About Acrivon Therapeutics, Inc.
Acrivon (NASDAQ: ACRV) is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.
Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2b trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.
In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company’s clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed at DL3. In addition, the company is advancing a preclinical program directed against an undisclosed cell cycle regulatory target.
Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.
Position Overview:
The Senior Scientist/Principal Scientist, Bioinformatics, within the Data Science team will play a central role in developing and applying advanced computational approaches to support drug discovery and development, leveraging Acrivon’s generative phosphoproteomics AP3 platform.
We are seeking a highly accomplished scientist with expertise in building scalable analytical workflows, applying rigorous quantitative methods, and extracting actionable biological insights from large-scale omics data. The successful candidate will lead analyses across proteomics, phosphoproteomics, transcriptomics, and other high-dimensional datasets, integrating these data with systems biology and AI/ML approaches to inform target discovery, mechanism-of-action studies, indication selection, and biomarker identification. Experience in proteomics-driven pathway analysis and network biology will be highly valued.
This individual will work closely within a multidisciplinary environment that includes proteomics, biology, and biomarker teams to maximize the scientific and translational value of Acrivon’s AP3 platform.
This role is based in Watertown, MA.
Duties and Responsibilities:
- Lead computational analysis and interpretation of large-scale proteomics and other multi-omics datasets to support mechanism-of-action studies, indication prioritization, target identification and validation, and biomarker discovery.
- Design, develop, and optimize robust, scalable, and secure computational pipelines for proteomics and multi-omics data analysis.
- Develop and maintain interactive web-based applications and data visualization tools that enable robust analytics within a cloud-based environment.
- Evaluate and incorporate emerging bioinformatics, mass spectrometry proteomics, and AI/ML technologies into data science workflows and analytical pipelines.
- Apply advanced AI/ML approaches, including generative and agentic AI, to enhance biological interpretation, hypothesis generation, and data-driven decision-making.
- Partner closely with proteomics, biology, biomarker, and other cross-functional teams to deliver tailored analyses and actionable biological insights.
Qualifications include:
- D. or M.S. in Bioinformatics, Computational Biology, Computer Science, Engineering, or a related quantitative discipline, with 5+ years of industry experience in a biotechnology or pharmaceutical setting.
- Expertise in the computational analysis, integration, and visualization of large-scale omics datasets, with a particular emphasis on mass spectrometry-based proteomics.
- Proven track record of designing and implementing scalable computational workflows for large-scale omics datasets and translating analytical findings into actionable biological insights.
- Strong programming skills in R and Python, encompassing scripting, data wrangling, statistical analysis, and visualization.
- Experience building interactive analytical tools, visualizations, and enterprise-level web applications using frameworks such as R Shiny, Streamlit, Flask, or Django.
- Experience with cloud computing environments and scalable data infrastructure, including workflow orchestration and data management on cloud platforms.
- Experience with data integration strategies and biological database design, including systems for managing, storing, and retrieving large-scale omics datasets.
- Strong scientific knowledge of oncology, including cancer biology, signaling pathways, biomarkers, and therapeutic modalities.
- Experience with single-cell and/or spatial omics data analysis is preferred.
- Experience applying AI/ML approaches, such as generative AI, agentic workflows, knowledge graphs, large language models, or foundation models, to biological data interpretation or hypothesis generation is preferred.
Acrivon Therapeutics is proud to be an equal opportunity employer and to provide equal opportunities to all employees and applicants for employment without regard to race, color, religion, sex or gender identity, national origin, age, disability, sexual orientation or genetics. In addition to federal law requirements, Acrivon Therapeutics complies with applicable state and local laws governing nondiscrimination in employment.
See all 131+ Bioinformatics jobs
Sign up for free to unlock all listings, filter by visa type, and get alerts for new Bioinformatics roles.
Get Access To All JobsTips for Finding Bioinformatics Jobs
Position yourself at the intersection of computation and biology
Bioinformatics roles are strong H-1B candidates precisely because they require dual expertise that few domestic candidates possess. Emphasize both your programming skills and your understanding of genomic data, molecular biology, or structural biology in applications.
Target pharmaceutical companies with large genomics programs
Companies like Illumina, Roche, Novartis, and AstraZeneca have dedicated bioinformatics teams working on precision medicine and drug target identification. These employers regularly sponsor H-1B visas for bioinformatics scientists and engineers.
Build experience with cloud-scale genomic pipelines
The shift toward cloud-based genomic analysis on AWS and Google Cloud has created demand for bioinformaticians who can build scalable pipelines. Experience with tools like Nextflow, WDL, or Terra/Cromwell makes you particularly competitive for industry roles.
Pursue academic medical center positions for cap-exempt sponsorship
Bioinformatics positions at institutions like the Broad Institute, Memorial Sloan Kettering, or university genomics centers are H-1B cap-exempt. These roles combine cutting-edge research with visa certainty since no lottery is needed.
Contribute to open-source bioinformatics tools for visa evidence
Contributions to widely used tools like Bioconductor packages, Galaxy toolshed, or GATK workflows serve as evidence of expertise for O-1A or EB-1 petitions. Documented contributions to the scientific community strengthen extraordinary ability claims.
Bioinformatics jobs are hiring across the US. Find yours.
Find Bioinformatics JobsFrequently Asked Questions
Is bioinformatics in high demand for visa sponsorship?
Yes, bioinformatics professionals are in strong demand because the role sits at the intersection of biology and computer science. Pharmaceutical companies, biotech firms, and academic medical centers all need specialists who can analyze genomic data, build computational pipelines, and support drug discovery. The combination of life sciences and programming skills makes these roles difficult to fill domestically.
What degree do I need for a bioinformatics H-1B?
Most bioinformatics H-1B petitions require at least a bachelor's degree in bioinformatics, computational biology, computer science, or a closely related field. A master's or Ph.D. strengthens the petition and can qualify you for the H-1B advanced degree exemption. The key is demonstrating that the role requires specialized knowledge at the intersection of biology and computation.
How to find Bioinformatics jobs with visa sponsorship?
To find Bioinformatics jobs with visa sponsorship, use Migrate Mate, which specializes in connecting international candidates with sponsored opportunities. Focus on biotech companies, pharmaceutical firms, and research institutions that commonly sponsor H-1B, O-1, or TN visas for bioinformatics specialists. These employers often need computational biologists, genomic data analysts, and bioinformatics software developers for drug discovery and research projects.
Should I pursue bioinformatics in pharma or academia for visa sponsorship?
Both paths have advantages. Academic positions at universities and research hospitals are H-1B cap-exempt with no lottery requirement. Pharmaceutical companies like Pfizer, Roche, and Novartis sponsor at higher salaries but are subject to the annual cap. Your choice may depend on whether you prioritize visa certainty or compensation.
What programming skills do bioinformatics employers look for?
Python, R, and Linux/Bash scripting are foundational. Employers also value experience with bioinformatics tools like BLAST, Bowtie, and Galaxy, as well as cloud platforms (AWS, Google Cloud) for large-scale genomic data processing. SQL and workflow managers like Nextflow or Snakemake are increasingly requested.
What is the prevailing wage requirement for sponsored Bioinformatics jobs?
When a U.S. employer sponsors a foreign worker for a work visa, they are legally required to pay at least the "prevailing wage" — the average wage paid to workers in the same occupation, in the same geographic area, with similar experience. This is set by the Department of Labor to prevent employers from hiring foreign workers at below-market rates. The prevailing wage varies significantly by role, location, and experience level — for example, a bioinformatics in California will have a different prevailing wage than the same role in a smaller state. You can look up current prevailing wage rates for any occupation and location using the OFLC Wage Search.
See which Bioinformatics employers are hiring and sponsoring visas right now.
Search Bioinformatics Jobs